Daniel F. Battafarano

Daniel F. Battafarano

Auto-generated profile, based on publicly available information

Daniel F. Battafarano

San Antonio Military Medical Center San Antonio Texas

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2018 in Arthritis Care & Research
Verified
Journal Article
Closed access
PDF file
DBDaniel F. Battafarano
Daniel F. Battafarano
MDMarcia Ditmyer
Marcia Ditmyer
MBMarcy B. Bolster
Marcy B. Bolster
John FitzGeraldJohn FitzGerald
John FitzGerald
CDChad Deal
Chad Deal
SMSeetha U. Monrad
Seetha U. Monrad

24 June 2008 in Arthritis Care & Research
Verified
Journal Article
Closed access
PDF file
ACAngelique N. Collamer
Angelique N. Collamer
KGKaren T. Guerrero
Karen T. Guerrero
JHJeffery S. Henning
Jeffery S. Henning
DBDaniel F. Battafarano
Daniel F. Battafarano

27 January 2014 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
IRInmaculada del Rincón
Inmaculada del Rincón
DBDaniel F. Battafarano
Daniel F. Battafarano
JRJose F. Restrepo
Jose F. Restrepo
JEJohn M. Erikson
John M. Erikson
AEAgustín Escalante
Agustín Escalante

1 December 2010 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
ACAngelique N. Collamer
Angelique N. Collamer
DBDaniel F. Battafarano
Daniel F. Battafarano

28 January 2011 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
MEMatthew R. Evans
Matthew R. Evans
AEAgustín Escalante
Agustín Escalante
DBDaniel F. Battafarano
Daniel F. Battafarano
GFGregory L. Freeman
Gregory L. Freeman
DODaniel H. O'LEary
Daniel H. O'LEary
IRInmaculada del Rincón
Inmaculada del Rincón
Objective: The role of atherosclerosis in the acute coronary syndromes (ACS) that occur in patients with rheumatoid arthritis (RA) has not been quantified in detail. We undertook this study to determine the extent to which ACS are associated with carotid atherosclerosis in RA.Methods: We prospectively ascertained ACS, defined as myocardial infarction, unstable angina, cardiac arrest, or death due to ischemic heart disease, in an RA cohort. We measured carotid atherosclerosis using high‐resolution ultrasound. We used Cox proportional hazards models to estimate the association between ACS and atherosclerosis, adjusting for demographic features, cardiovascular (CV) risk factors, and RA manifestations.Results: We performed carotid ultrasound on 636 patients whom we followed up for 3,402 person‐years. During this time, 84 patients experienced 121 new or recurrent ACS events, a rate of 3.5 ACS events per 100 patient‐years (95% confidence interval [95% CI] 3.0–4.3). Among the 599 patients without a history of ACS, 66 incident ACS events occurred over 3,085 person‐years, an incidence of 2.1 ACS events per 100 person‐years (95% CI 1.7–2.7). The incidence of new ACS events per 100 patient‐years was 1.1 (95% CI 0.6–1.7) among patients without plaque, 2.5 (95% CI 1.7–3.8) among patients with unilateral plaque, and 4.3 (95% CI 2.9–6.3) among patients with bilateral plaque. Covariates associated with incident ACS events independent of atherosclerosis included male sex, diabetes mellitus, and a cumulative glucocorticoid dose of ≥20 gm.Conclusion: Atherosclerosis is strongly associated with ACS in RA. RA patients with carotid plaque, multiple CV risk factors (particularly diabetes mellitus or hypertension), many swollen joints, and a high cumulative dose of glucocorticoids, as well as RA patients who are men, are at high risk of ACS.

1 June 2015 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
IRInmaculada del Rincón
Inmaculada del Rincón
JPJoseph F Polak
Joseph F Polak
DODaniel H O'LEary
Daniel H O'LEary
DBDaniel F Battafarano
Daniel F Battafarano
JEJohn M Erikson
John M Erikson
AEAgustín Escalante
Agustín Escalante
Objective To estimate atherosclerosis progression and identify influencing factors in rheumatoid arthritis (RA). Methods We used carotid ultrasound to measure intima-media thickness (IMT) in RA patients, and ascertained cardiovascular (CV) risk factors, inflammation markers and medications. A second ultrasound was performed approximately 3 years later. We calculated the progression rate by subtracting the baseline from the follow-up IMT, divided by the time between the two scans. We used logistic regression to identify baseline factors predictive of rapid progression. We tested for interactions of erythrocyte sedimentation rate (ESR) with CV risk factors and medication use. Results Results were available for 487 RA patients. The mean (SD) common carotid IMT at baseline was 0.571 mm (0.151). After a mean of 2.8 years, the IMT increased by 0.050 mm (0.055), p≤0.001, a progression rate of 0.018 mm/year (95% CI 0.016 to 0.020). Baseline factors associated with rapid progression included the number of CV risk factors (OR 1.27 per risk factor, 95% CI 1.01 to 1.61), and the ESR (OR 1.12 per 10 mm/h, 95% CI 1.02 to 1.23). The ESR×CV risk factor and ESR×medication product terms were significant, suggesting these variables modify the association between the ESR and IMT progression. Conclusions Systemic inflammation and CV risk factors were associated with rapid IMT progression. CV risk factors may modify the role of systemic inflammation in determining IMT progression over time. Methotrexate and antitumour necrosis factor agents may influence IMT progression by reducing the effect of the systemic inflammation on the IMT.